iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable
FastPharming Manufacturing System®, today
announced a research collaboration with the University of Texas
Southwestern Medical Center (“UT Southwestern”) to explore in solid
tumors the anti-cancer potential of the molecule that is part of
the IBIO-100 program.
Among all the stromal cells that present in the
tumor microenvironment, cancer-associated fibroblasts (“CAFs”) are
one of the most abundant and critical components of tumor tissue,
which provide physical support for tumor cells and can promote or
retard tumorigenesis in a context-dependent manner. CAFs are also
involved in the modulation of many components of the immune system,
and recent studies have revealed their roles in immune evasion and
poor responses to cancer immunotherapy.1 In addition, CAF response
to chemotherapy is highly variable.2
Through a series of planned in vitro and in vivo
studies, the collaboration will evaluate the potential of the
anti-fibrotic effects of iBio’s endostatin E4 molecule to improve
the efficacy of concomitant treatments, such as chemotherapy and
immunotherapy, in cancer models with a fibrotic component. The
Company is currently developing endostatin E4 as IBIO-100 for
fibrotic diseases.
“We are thrilled to combine our efforts with one
of the world’s leading fibrotic tumor cancer research labs at one
of the premier academic medical centers in the nation,” said Tom
Isett, Chairman and Chief Executive Officer at iBio. “IBIO-100 has
shown strong therapeutic potential in preclinical models of two
major fibrotic diseases, systemic scleroderma and idiopathic
pulmonary fibrosis, and we look forward to exploring these same
potentially transformative benefits in the treatment of solid
tumors.”
“Through many years of research, we have come to
understand that an overabundant fibrotic tumor microenvironment is
associated with poor cancer treatment outcomes,” commented Martin
Brenner, DVM. Ph.D., iBio’s Chief Scientific Officer. “We have also
learned that destruction of CAFs can lead to worse prognosis, not
better.3 We believe that our endostatin E4 molecule has the
potential to normalize fibrosis without the detrimental effects of
CAF destruction, thereby improving responses to current standard of
care treatments such as chemotherapy and immunotherapy. We look
forward to exploring this potential with our partners at UT
Southwestern.”
References
1 Liu, T., Han, C., Wang, S. et al.
Cancer-associated fibroblasts: an emerging target of anti-cancer
immunotherapy. J Hematol Oncol 12, 86 (2019).
https://doi.org/10.1186/s13045-019-0770-1
2 Sonnenberg, M., van der Kuip, H., Haubeiß, S.
et al. Highly variable response to cytotoxic chemotherapy in
carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC
Cancer 8, 364 (2008). https://doi.org/10.1186/1471-2407-8-364
3 Chandler C, Liu T, Buckanovich R, Coffman LG.
The double edge sword of fibrosis in cancer. Translational
Research. 2019;209:55–67.
https://doi.org/10.1016/j.trsl.2019.02.006
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals
and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines
vertical farming, automated hydroponics, and novel
glycosylation technologies to
rapidly develop high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is
developing proprietary biopharmaceuticals for the treatment of
cancers, as well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along
with Glycaneering Development Services™
for advanced recombinant protein design. For more information,
visit www.ibioinc.com.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding plans to explore the anti-cancer
potential of the molecule that is part of the IBIO-100 program also
in solid tumors, plans to evaluate the potential of the
anti-fibrotic effects of iBio’s endostatin E4 molecule to improve
the efficacy of concomitant treatments, such as chemotherapy and
immunotherapy, in cancer models with a fibrotic component in a
series of in vitro and in vivo studies, the therapeutic potential
of IBIO-100 in preclinical models of two major fibrotic diseases,
systemic scleroderma and idiopathic pulmonary fibrosis, exploring
the therapeutic potential of IBIO-100 in the treatment of cancer,
the potential of iBio’s endostatin E4 molecule to normalize
fibrosis without the detrimental effects of CAF destruction and
improving responses to current standard of care treatments such as
chemotherapy and immunotherapy. While the Company believes
these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements, which
are based on information available to us on the date of this
release. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the Company’s ability to complete clinical
trials and in vitro and in vivo studies on time and achieve desired
results and benefits as expected, the Company’s ability to obtain
regulatory approvals for commercialization of product candidates or
to comply with ongoing regulatory requirements, regulatory
limitations relating to the Company’s ability to promote or
commercialize its product candidates for specific indications,
acceptance of the Company’s product candidates in the marketplace
and the successful development, marketing or sale of the Company’s
products, the Company’s ability to maintain its license agreements,
the continued maintenance and growth of the Company’s patent
estate, the Company’s ability to establish and maintain
collaborations, the Company’s ability to obtain or maintain the
capital or grants necessary to fund its research and development
activities and whether the Company will incur unforeseen expenses
or liabilities or other market factors, successful compliance with
governmental regulations applicable to its manufacturing
facilities, competition, the Company’s ability to retain its key
employees or maintain its NYSE American listing, the Company’s
ability to increase its authorized shares, and the other factors
discussed in the Company’s filings with the SEC including the
Company’s Annual Report on Form 10-K for the year ended June 30,
2021, and the Company’s subsequent filings with the SEC on Forms
10-Q and 8-K. The information in this release is provided only as
of the date of this release, and the Company undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024